Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
AssigneeRegeneren Pharmaceuticals, Inc.
InventorsRobert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
Claims28
A vector comprising a polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO:
- 832, wherein said HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 680, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 682, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:
- 684.
A vector comprising a polynucleotide encoding a light chain variable region (LCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO:
- 832, wherein said LCVR comprises three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3), wherein said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 688, said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 650, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:
- 690.
A lipid nanoparticle comprising a polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO:
- 832, wherein said HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 680, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 682, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:
- 684.
A lipid nanoparticle comprising a polynucleotide encoding a light chain variable region (LCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO:
- 832, wherein said LCVR comprises three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3), wherein said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:
- 688, said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:
- 650, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:
- 690.
Dependencies are inferred from the claim text.